| 黄爱君,夏愔愔,詹思延,张耀文,舒正.抗结核治疗中预防应用保肝药临床试验的中文文献系统评价[J].Chinese journal of Epidemiology,2010,31(7):826-827 |
| 抗结核治疗中预防应用保肝药临床试验的中文文献系统评价 |
| Effectiveness and safety of preventive usage of liver protective drugs during anti-tuberculosis therapy: a systematic review of clinical trials in China |
| Received:November 04, 2009 |
| DOI： |
| KeyWord: 抗结核药 肝损伤 临床试验 保肝药 |
| English Key Word: Anti-tubercular agents Hepatitis,druginduced Clinical trials Hepatoprotector |
| FundProject:全球基金(TB07-030) |
| Author Name | Affiliation | E-mail | | HUANG Ai-jun | Teaching and Researching Division of Pharmacology, School of Basic Medical Sciences, Jiujiang University, Key Laboratory of Jiangxi University for the Systems Biology Clinical Application, Jiujiang 332000, China | | | XIA Yin-yin | Department of Epidemiology and Biostatistics, School of Public Health, Peking University | | | ZHAN Si-yan | Department of Epidemiology and Biostatistics, School of Public Health, Peking University | siyan-zhan@bjmu.edu.cn | | ZHANG Yao-wen | Department of Epidemiology and Biostatistics, School of Public Health, Peking University | | | SHU Zheng | Department of Epidemiology and Biostatistics, School of Public Health, Peking University | |
|
| Hits: 2338 |
| Download times: 0 |
| Abstract: |
| 国结核病负担较高，每年仅新发现的初复治病例即达98万?，加上原患未治愈者，每年接受治疗的病例超过100万。抗结核治疗使用的一、二线药物均可引起不良反应，其中影响最大且发病率较高的为肝损害陋)。为避免肝损害的发生，目前我国临床上常在抗结核治疗开始时，即予保护肝脏的药物。这种预防性使用在其他国家极为少见【31，且是否确实有效也存在一些争论。本研究计划通过对近lO年来公开发表的相关临床试验进行系统评价，以了解我国在该领域的研究进展和初步结果。 |
| English Abstract: |
| |
|
View Fulltext
Html FullText
View/Add Comment Download reader |
| Close |
|
|
|